Cholecystitis

The pathophysiology of cholecystitis involves a complex interplay of mechanical obstruction, chemical irritation, and secondary infection. While traditionally viewed as a localized disease of the gallbladder, modern evidence suggests that acute acalculous cholecystitis (AAC) may represent a manifestation of systemic critical illness, whereas acute calculous cholecystitis (ACC) is primarily driven by local mechanical factors ^[17]D.

Mechanisms of Calculous Cholecystitis (ACC)

In over 90% of cases, the primary trigger is the obstruction of the cystic duct by a gallstone. However, cystic duct obstruction alone is often insufficient to induce acute inflammation; the composition of the bile and the functional state of the gallbladder wall are critical determinants ^[13]D.

Step-by-Step Mechanism of ACC:

1. Cystic Duct Obstruction: A gallstone becomes impacted in the cystic duct or the neck of the gallbladder (Hartmann's pouch).
2. Bile Stasis and Chemical Irritation: Stasis leads to the concentration of lithogenic bile. High concentrations of cholesterol increase the rate of cholesterol diffusion through the gallbladder wall ^[13]D.
3. Cellular Dysfunction: Cholesterol is incorporated into the sarcolemmae of gallbladder muscle cells via caveolin proteins. High caveolar cholesterol levels inhibit the tyrosine-induced phosphorylation of caveolin proteins, which is required to transfer receptor-G protein complexes into recycling endosomes ^[13]D.
4. Hypomotility: This molecular inhibition results in gallbladder hypomotility, creating a permissive environment where hydrophobic bile salts can inflame the mucosa and further impair muscle function ^[13]D.
5. Inflammatory Cascade: The damaged mucosa releases inflammatory mediators, including prostaglandins and Vascular Endothelial Growth Factor A (VEGF-A), which promote vascular permeability and edema ^[5].

Mechanisms of Acalculous Cholecystitis (AAC)

AAC occurs in the absence of gallstones and is frequently seen in critically ill patients. The pathogenesis is multifactorial, primarily driven by bile stasis and ischemia ^[4]C[6]D. In these patients, the gallbladder is particularly susceptible to hypoperfusion due to its end-arterial blood supply (the cystic artery).

Pathogenic Drivers of AAC:

• Ischemia-Reperfusion Injury: Systemic hypotension, sepsis, or major surgery (e.g., gastric operations) leads to reduced cystic artery flow ^[4]C[6]D.
• Bile Toxicity: Prolonged fasting and total parenteral nutrition (TPN) lead to a lack of cholecystokinin (CCK) stimulation, resulting in gallbladder distension and the accumulation of highly concentrated, toxic bile ^[10]D.
• Endothelial Dysfunction: In COVID-19 patients, SARS-CoV-2 enters cells by binding the spike protein to angiotensin-converting enzyme 2 (ACE2) receptors expressed on the epithelial cells of the gastrointestinal tract and gallbladder, potentially causing direct viral cholecystitis ^[8]D[18]C.
• Immunological Triggers: Q fever (Coxiella burnetii) has been associated with a dose-dependent increase in IgG anticardiolipin antibodies, which may contribute to the vascular complications seen in acalculous cases ^[1].

Molecular and Cellular Pathways

Inflammation is propagated by specific cellular responses and neurohumoral dysregulation. In chronic cases, there is significant alteration in the adrenergic and cholinergic regulation of the gallbladder tone, often comorbid with systemic conditions like chronic obstructive pulmonary disease ( COPD ) ^[16].

The Role of VEGF-A and Angiogenesis

VEGF-A is a potent proangiogenic agent that is significantly upregulated in gallbladder inflammation and carcinogenesis ^[5]. It increases microvascular permeability, contributing to the gallbladder wall thickening (edema) seen on imaging. High expression of VEGF-A is associated with more advanced tissue damage and poor prognosis ^[5].

Immune Cell Exhaustion

Recent single-cell RNA sequencing has identified that metabolic abnormalities, such as those in Wilson's disease (impaired copper metabolism), alter the hepatic immune microenvironment ^[20]D. Specifically, the exhaustion of Natural Killer (NK) cells is a fundamental factor that predicts a poorer prognosis and higher incidence of cholecystitis by impairing the innate immune response to biliary pathogens ^[20]D.

Autoimmune and Fibroinflammatory Mechanisms

IgG4-related cholecystitis is a distinct fibroinflammatory entity. It is characterized by a dense lymphoplasmacytic infiltrate and storiform fibrosis ^[9]D.

• Target Antigens: While specific antigens are still being identified, the disease frequently targets the periductal glands around the bile ducts ^[12]D.
• Pathway: Activation of Th2-dependent immune responses and regulatory T cells leads to the overproduction of IgG4 and subsequent tissue fibrosis ^[12]D.

Microbiology and Bactibilia

While bile is normally aseptic, bactibilia (bacterial colonization of bile) occurs in 20% to 70% of cholecystitis cases ^[3]. This is typically a secondary event following stasis and initial chemical inflammation.

The clinical evaluation of suspected cholecystitis requires a systematic approach to differentiate it from simple biliary colic and other acute abdominal pathologies. While biliary colic is characterized by transient pain, acute cholecystitis (AC) involves persistent inflammation of the gallbladder wall, typically resulting from prolonged cystic duct obstruction ^[22][24].

Presenting Symptoms

Patients with acute cholecystitis typically present with steady, severe pain located in the right upper quadrant (RUQ) or epigastrium. Unlike the intermittent nature of biliary colic, the pain in AC persists for more than 6 hours and is often associated with systemic symptoms such as fever, nausea, and vomiting ^[24][25]C.

• Pain Characteristics: The onset is often sudden, frequently occurring after the ingestion of a high-fat meal. The pain is visceral in origin but becomes somatic as the overlying parietal peritoneum becomes inflamed.
• Radiation: Radiation to the right shoulder or the inferior angle of the right scapula (Boas' sign) is a classic finding, though its sensitivity is variable.
• Systemic Features: Fever and tachycardia are common. In cases of cystic artery pseudoaneurysm (a rare but severe complication), patients may present with Quincke's triad: RUQ pain, hemobilia (manifesting as gastrointestinal bleeding), and obstructive jaundice ^[25]C.
• Socioeconomic Factors: Patients residing in "food deserts" (low-income areas with low access to healthy food) may present with increased biliary disease severity, potentially due to higher rates of obesity and delayed access to care ^[29]D.

Physical Examination Findings

A focused abdominal examination is the cornerstone of diagnosis. The clinician should assess for signs of localized peritonitis and specific gallbladder-related maneuvers.

• Murphy's Sign: This is the most specific physical exam finding for AC. The examiner places their hand at the right costal margin at the midclavicular line and asks the patient to take a deep breath. A positive sign is the abrupt arrest of inspiration as the inflamed gallbladder descends and contacts the examiner's hand.
• Localized Guarding and Rebound Tenderness: These findings suggest parietal peritoneal irritation. If generalized peritonitis is present, gallbladder perforation or gangrenous cholecystitis should be suspected.
• Palpable Mass: In approximately 20% of cases, an enlarged, tender gallbladder may be palpable in the RUQ.
• Jaundice: While not typical for uncomplicated cholecystitis, mild jaundice may occur due to inflammation extending to the common bile duct (CBD) or Mirizzi syndrome. Significant jaundice (bilirubin >4 mg/dL) should prompt evaluation for choledocholithiasis ^[25]C[31]D.

Phenotypic Variants

Cholecystitis can present in several distinct clinical forms, each with unique historical and examination features.

Red Flags

Certain clinical findings necessitate urgent surgical or interventional consultation to prevent significant morbidity or mortality:

1. Quincke's Triad: RUQ pain, hemobilia, and jaundice; suggests a cystic artery pseudoaneurysm ^[25]C.
2. High Fever and Rigors: May indicate ascending cholangitis or gallbladder empyema.
3. Generalized Peritonitis: Suggests gallbladder perforation.
4. Hemodynamic Instability: Tachycardia and hypotension in the setting of RUQ pain may indicate sepsis or internal hemorrhage from a vascular complication ^[25]C.

Atypical Presentations

Clinicians must maintain a high index of suspicion in populations where classical signs may be absent or misleading.

• Pediatric Patients: In children, the common bile duct is normally <4 mm; dilation beyond this threshold, even without laboratory abnormalities, should raise suspicion for biliary pathology ^[31]D. Eosinophilic cholecystitis should be considered in children presenting with typical symptoms but atypical risk factors ^[26]C.
• Sickle Cell Disease (SCD): Up to 85% of SCD patients develop gallstones by their third decade. These patients often have baseline hemolysis , making the interpretation of jaundice and RUQ pain (which can mimic a vaso-occlusive crisis) challenging ^[32]D.
• Elderly and Diabetic Patients: These individuals may present with vague symptoms, such as malaise or localized discomfort, without a significant fever or a positive Murphy's sign.
• Recurrence Risk: Patients with low skeletal muscle mass (low psoas muscle mass index) and high visceral adiposity are at a significantly higher risk for the recurrence of acute cholecystitis after conservative management ^[23].

The clinical presentation of acute cholecystitis (AC) ranges from localized inflammatory pain to life-threatening systemic sepsis. While the classic presentation involves right upper quadrant (RUQ) pain and fever, clinicians must recognize that the clinical phenotype is heavily influenced by patient comorbidities, such as diabetes mellitus and recent viral infections, which can mask symptoms or accelerate progression to necrosis ^[33][35]D.

Presenting Symptoms

Patients typically present with a history of biliary colic that, instead of resolving within hours, becomes persistent and intensifies. The pain is localized to the RUQ or epigastrium and frequently radiates to the right scapula or shoulder. Unlike simple colic, AC is characterized by an inflammatory timeline where symptoms progress over days; if the inflammatory process is not interrupted, the risk of gallbladder wall ischemia and subsequent gangrene increases significantly after the first 48 to 72 hours ^[47][48]D.

• Pain Characteristics: Constant, severe RUQ pain, often accompanied by nausea and vomiting.
• Systemic Features: Low-grade fever is common, but high-grade fever or rigors should raise immediate suspicion for gangrenous or emphysematous variants ^[40][41]D.
• Progression: Symptoms typically reach a nadir of severity if untreated, leading to complications like perforation or abscess formation ^[44]D.

Physical Examination Findings

A systematic physical examination is essential to differentiate uncomplicated AC from severe variants. The examination should be organized by systemic and localized findings to assess for impending clinical deterioration.

Step-by-Step Physical Examination Protocol:

1. Systemic Assessment: Evaluate for tachycardia and hypotension. Autonomic instability often precedes overt peritonitis in patients with gangrenous cholecystitis (GC) ^[40].
2. Inspiratory Arrest (Murphy’s Sign): Palpate the RUQ while the patient takes a deep breath. A positive test is the cessation of inspiration due to pain as the inflamed gallbladder touches the peritoneum. While sensitive, this may be absent in the elderly or those with advanced neuropathy ^[35]D[54]D.
3. Palpation for Mass: A palpable, tender gallbladder is present in approximately 20% of cases and may indicate a phlegmon or pericholecystic abscess ^[44]D.
4. Peritoneal Signs: Assess for guarding and rebound tenderness. Generalized peritonitis suggests gallbladder perforation into the free peritoneal cavity ^[44]D.

Phenotypic Variants

Cholecystitis presents in several distinct pathological forms, each with unique clinical implications and risks for surgical conversion.

Red Flags

Certain clinical and laboratory markers serve as "red flags" for gangrenous cholecystitis, which may be present in up to 42.6% of emergency cholecystectomy cases ^[47]. Early recognition is vital because GC is associated with higher morbidity and longer hospital stays ^[40].

• Advanced Age and Comorbidities: Patients > 51 years or those with hypertension and diabetes are at significantly higher risk for GC ^[37][47].
• Laboratory Thresholds: A WBC count > 13.0 x 10^9/L or a Neutrophil-to-Lymphocyte Ratio (NLR) > 5.48 are strong predictors of gallbladder gangrene ^[46][55]D.
• Biochemical Markers: Elevated D-dimer and Fibrinogen levels, along with hyponatremia or hypokalemia, are associated with severe inflammatory necrosis ^[55]D.
• Imaging Markers: A gallbladder width > 4 cm or the presence of intraluminal membranes on ultrasound are highly specific for gangrene ^[39][55]D.

Atypical Presentations

Clinicians must maintain a high index of suspicion in populations where the classic "surgical abdomen" may be absent.

• Diabetes Mellitus: Chronic hyperglycemia impairs neutrophil chemotaxis and oxidative burst, which can lead to severe infections like emphysematous cholecystitis while neuropathy masks visceral pain ^[35]D.
• The Elderly: Often present with vague symptoms such as malaise or anorexia rather than localized RUQ pain. Delayed diagnosis in this group leads to a higher frequency of gangrenous and perforated cases ^[54]D.
• COVID-19 Patients: Recent data indicates that COVID-19 infection is a significant risk factor for death in patients with AC. These patients show a higher incidence of gangrenous changes and adverse outcomes compared to the general population ^[33].
• Malignancy Mimics: XGC and rare gallbladder metastases (e.g., from renal cell carcinoma ) can present with clinical and imaging features indistinguishable from acute cholecystitis or gallbladder cancer, often requiring advanced imaging like PET/CT or EUS for differentiation ^{[49]D[52]D[56]C[57]C}.

The diagnosis of acute cholecystitis (AC) requires a multi-modal approach that integrates clinical findings, laboratory markers, and diagnostic imaging. While the clinical presentation often begins with right upper quadrant (RUQ) pain and a positive Murphy’s sign, these findings alone are insufficient for a definitive diagnosis, particularly in complex cases or critically ill patients ^[6]D[83]D. Modern diagnostic protocols rely on the Tokyo Guidelines 2018 (TG18) to provide a standardized framework for diagnosis and severity stratification ^[74][83]D.

Diagnostic Criteria

According to the TG18 framework, a definitive diagnosis of acute cholecystitis is established when one item from each of the following three categories is present ^[74][83]D:

• A. Local Signs of Inflammation: A positive Murphy’s sign (arrest of inspiration on deep palpation of the RUQ) or the presence of RUQ pain, tenderness, or a palpable mass.
• B. Systemic Signs of Inflammation: Fever, elevated C-reactive protein (CRP), or an elevated white blood cell (WBC) count.
• C. Imaging Findings: Characteristic findings of acute cholecystitis on ultrasound, CT, or HIDA scan.

A suspected diagnosis is made if one item from Category A and one from Category B are present. A definitive diagnosis requires confirmation via Category C ^[83]D.

Laboratory Tests

Laboratory evaluation is essential for assessing the systemic inflammatory response and identifying potential complications such as common bile duct (CBD) stones or gangrenous changes. Standard orders include a complete blood count (CBC), liver function tests (LFTs), and inflammatory markers ^[74][81]D.

• Inflammatory Markers: Leukocytosis and elevated CRP are common but lack high specificity. Recent evidence suggests the Triglyceride-Glucose (TyG) index—calculated as ln (fasting triglyceride × fasting glucose / 2)—serves as a valuable biomarker for metabolic stress and inflammation. A higher TyG index is significantly associated with increased disease severity ^[74].
• Liver Function Tests: Elevations in bilirubin, alkaline phosphatase, or aminotransferases may suggest biliary obstruction or Mirizzi syndrome. However, predicting CBD stones in the setting of AC remains challenging; current prediction models often require external validation to improve positive predictive values (PPV) above the 75% threshold required for direct ERCP ^[81]D.
• IgG4 Levels: In rare cases of isolated gallbladder swelling mimicking a neoplasm, serum IgG4 levels should be checked to rule out IgG4-related cholecystitis, a manifestation of IgG4-related disease (IgG4-RD) ^[73]C.

Imaging Modalities

Ultrasonography (US)

Transabdominal ultrasound remains the first-line imaging modality due to its high sensitivity and availability. Key findings include gallbladder wall thickening (>4 mm), pericholecystic fluid, and the presence of gallstones or sludge ^[28]D. A critical, highly specific marker is the peak systolic cystic artery velocity (CaV). A CaV ≥ 40 cm/s has been proposed as an independent sonographic predictor of AC in the emergency setting, offering high specificity for the diagnosis ^[28]D.

Computed Tomography (CT)

While US is preferred for stones, CT is superior for identifying complications such as perforation, abscess, or gangrenous cholecystitis (GC) ^[34][69]. Advanced diagnostic techniques now utilize self-supervised learning (SSL) models that integrate plain and contrast-enhanced CT images to preoperatively identify GC with higher accuracy than traditional radiologist interpretation ^[34].

Cholescintigraphy (HIDA Scan)

HIDA remains the gold standard for assessing cystic duct patency. Failure of the gallbladder to visualize within 60 minutes (or up to 4 hours with delayed imaging) is diagnostic of cystic duct obstruction, the hallmark of AC.

Advanced Diagnostic Modalities

In patients who are surgically unfit or have complex anatomy, Endoscopic Ultrasound (EUS) is increasingly utilized. EUS allows for high-resolution imaging of the gallbladder wall and the biliary tree, and it can facilitate EUS-guided gallbladder drainage (EUS-GBD) using lumen-apposing metal stents (LAMS) if the diagnosis is confirmed and intervention is required ^[64][76]D. For patients with suspected CBD stones, EUS or MRCP is preferred over direct ERCP unless the probability of stones is high ^[81]D.

Diagnostic Algorithm

The workup of suspected acute cholecystitis should follow a structured sequence to ensure rapid diagnosis and grading:

1. Step 1: Clinical Assessment: Evaluate for RUQ pain and Murphy’s sign. Assess for systemic symptoms (fever, tachycardia).
2. Step 2: Laboratory Workup: Order CBC, CRP, LFTs, and calculate the TyG index to assist in severity stratification ^[74].
3. Step 3: Primary Imaging: Perform RUQ ultrasound. Look for wall thickening, stones, and measure cystic artery velocity ^[28]D.
4. Step 4: Advanced Imaging (if needed): If US is equivocal or complications (e.g., gangrene, perforation) are suspected, obtain a contrast-enhanced CT ^[34]. If CBD stones are suspected based on LFTs, consider MRCP or EUS ^[81]D.
5. Step 5: Severity Grading: Apply TG18 criteria to grade the AC as Grade I (mild), Grade II (moderate), or Grade III (severe) to guide management ^[83]D.

The management of acute cholecystitis (AC) requires a dual-track approach: immediate physiological stabilization and the strategic selection of surgical or drainage interventions based on disease severity and patient comorbidities. While laparoscopic cholecystectomy remains the gold standard, the presence of complications such as perforation, biliary-enteric fistulas, or a "difficult gallbladder" necessitates specific protocols to mitigate morbidity ^[58][69].

Step 1: Initial Assessment and Severity Classification

Upon presentation, clinicians must classify the severity of AC to determine the appropriate disposition and timing of intervention.

• Grade I (Mild): Localized inflammation without organ dysfunction. These patients are typically managed on a surgical ward ^[87].
• Grade II (Moderate): Characterized by marked local inflammation (e.g., gangrenous cholecystitis, palpable mass, or symptoms >72 hours). These patients require aggressive monitoring and early surgical intervention ^[88][96].
• Grade III (Severe): Associated with organ dysfunction (cardiovascular, neurological, respiratory, renal, hepatic, or hematological). These patients frequently require ICU admission for stabilization before or after intervention ^[70].

Step 2: Fluid Resuscitation and Antimicrobial Therapy

Immediate intravenous access is essential for fluid resuscitation and the administration of empirical antibiotics .

• Fluid Resuscitation: Aggressive crystalloid administration is required to correct dehydration and electrolyte imbalances caused by vomiting and decreased oral intake.
• Antibiotic Selection: For patients with mild-to-moderate AC, Cefazolin 1 g IV daily for 3 days during hospitalization, followed by oral antibiotics for 4 days post-discharge, has been shown to reduce infectious complications ^[88]. While preoperative antibiotics are standard for Grade II and III, their utility in Grade I (mild) cases is debated, as some evidence suggests they may not significantly alter outcomes in low-risk patients undergoing early surgery ^[87].

Step 3: Analgesia and Procedural Pain Control

Effective pain management is critical for patient comfort and early mobilization.

• Nerve Blocks: For patients undergoing laparoscopic surgery, ultrasound-guided T7-11 intercostal nerve blocks or subcostal transversus abdominis plane (TAP) blocks using 40 mL of 0.3% ropivacaine significantly reduce the need for remedial analgesia (e.g., tramadol) within the first 24 hours postoperatively ^[21].
• Surgical Technique: The use of ultrasonic dissection instead of conventional electrocautery is preferred as it reduces operative time, intraoperative blood loss, and postoperative pain and nausea ^[62][89].

Step 4: Management of the "Difficult Gallbladder" and Perforation

When severe inflammation or distorted anatomy precludes the safe achievement of the "critical view of safety," clinicians must pivot to bailout strategies.

• Subtotal Cholecystectomy (STC): This is a validated bailout technique for the difficult gallbladder. Fenestrating STC (f-STC) and reconstituting STC (r-STC) are the two primary methods; however, STC is associated with higher rates of postoperative bile leaks compared to total cholecystectomy ^[58].
• Perforated Cholecystitis: Perforation is a rare but high-morbidity complication. Early cholecystectomy (during the same admission) is strongly preferred over interval cholecystectomy. Patients undergoing interval surgery for perforation have a significantly higher risk of conversion to open surgery (55.2% vs 35.3%) and a higher incidence of surgical site infections ^[69].
• Timing: Surgery should ideally be performed within 7 days of symptom onset. Delaying surgery beyond this window or waiting for a weekday rather than performing a weekend procedure does not necessarily improve safety and may increase the risk of complications ^[90][94].

Step 5: Resolution Criteria and Transition to Definitive Care

For patients unfit for immediate surgery, gallbladder drainage serves as a bridge to definitive treatment.

• Percutaneous Transhepatic Gallbladder Drainage (PTGBD): Recommended for high-risk surgical candidates (Grade II/III) who do not respond to conservative therapy ^[91][96]. While PTGBD relieves acute symptoms, it is associated with longer hospital stays (median 18.2 days) and higher ICU admission rates compared to direct surgery ^[70].
• EUS-Guided Gallbladder Drainage (EUS-GBD): An alternative for patients unfit for surgery. Interval cholecystectomy after EUS-GBD is technically challenging due to cholecystoenteric fistula formation but can be achieved with high technical success in specialized centers ^[86].
• Completion Cholecystectomy: If a subtotal cholecystectomy was initially performed, a completion cholecystectomy may be required later for symptomatic cholelithiasis (in 55.8% of cases) or recurrent AC (in 19.8% of cases), typically at an interval of approximately 47 months ^[60].

The prognosis for acute cholecystitis is generally excellent with timely intervention, particularly in patients undergoing early laparoscopic cholecystectomy . However, outcomes vary significantly based on patient age, the presence of comorbidities, and the severity of gallbladder inflammation at the time of presentation ^[92]. While the majority of patients achieve a full recovery, a subset experiences long-term sequelae such as post- cholecystectomy syndrome or requires secondary interventions for biliary remnants ^[60].

Overall Recovery and Mortality

For most patients, the clinical course following surgical intervention is favorable. In the emergency setting, robotic-assisted procedures have shown a conversion rate to open surgery of approximately 9.1%, with overall complication rates near 13.2%, which are comparable to traditional laparoscopic methods ^[61]. In high-risk surgical candidates who are managed non-operatively or with drainage, the prognosis is more guarded.

While elective procedures carry minimal risk, emergency surgical treatment for acute cholecystitis in unselected populations can see a mortality 3-7%, particularly when complicated by perforation or sepsis ^[92]. Following successful surgery, approximately 80% return to independent functional status within 6 months, though elderly patients may experience a more protracted recovery period characterized by persistent fatigue or reduced mobility ^[92].

Prognostic Factors

The primary determinants of a poor prognosis include advanced age, male sex, and the presence of systemic inflammatory response syndrome (SIRS) ^[92]. The timing of surgery is also critical; for instance, in cases of perforated cholecystitis, patients undergoing interval (delayed) cholecystectomy are significantly more likely to require open surgery (55.2% vs 35.3%) and have higher rates of surgical site infections (17.2%) compared to those treated during the initial admission ^[69].

Long-term Sequelae and Post-Cholecystectomy Syndrome

A significant long-term consideration is the management of the "difficult gallbladder." When the critical view of safety cannot be achieved, surgeons may perform a subtotal cholecystectomy (STC) ^[58]. While STC is an effective bailout, it carries a risk of recurrent symptoms if a gallbladder remnant is left in situ.

1. Symptomatic Remnants: Approximately 55.8% of patients requiring a completion cholecystectomy (CC) present with symptomatic cholelithiasis in the remnant ^[60].
2. Timeline for Reintervention: The median interval from the initial subtotal surgery to a completion cholecystectomy is approximately 47 months ^[60].
3. Success of Reintervention: Completion cholecystectomy, though surgically challenging, achieves symptom resolution in 92.5% of cases ^[60].

Outcomes in Special Populations

Pregnancy

Acute cholecystitis is the second most common non-obstetric emergency during pregnancy ^[97]. Operative management is generally preferred over conservative treatment, as it reduces the risk of recurrence and subsequent emergency admissions, which can negatively impact fetal and maternal outcomes ^[97].

High-Risk Surgical Candidates

For patients unfit for surgery, Endoscopic ultrasound -guided gallbladder drainage (EUS-GBD) has emerged as a durable alternative to percutaneous drainage ^[64]. Long-term follow-up (>1 year) shows high technical and clinical success rates, though these patients remain at risk for stent-related complications or cholecystitis recurrence if the drainage is not definitive ^[64][67]. In patients who undergo percutaneous transhepatic gallbladder drainage (PTGBD), the risk of recurrence following tube removal marginalizes over time, provided the underlying biliary pathology is addressed ^[68].

Recurrence Risk

Recurrence is a primary concern in non-operative management. Patients treated with percutaneous cholecystostomy (PC) alone have higher rates of readmission and recurrent biliary events compared to those who eventually undergo interval cholecystectomy ^[98]. For those who do proceed to interval surgery after drainage, the approach (laparoscopic vs. robotic) and the method of dissection (ultrasonic vs. electrocautery) can influence short-term recovery, with ultrasonic dissection potentially reducing operative time and intraoperative blood loss ^[62][66].

The management of acute cholecystitis has undergone a significant paradigm shift over the last two decades, moving from a conservative 'cool-down' approach to early surgical intervention. This transition has been driven by high-quality evidence demonstrating that early laparoscopic cholecystectomy (LC) reduces hospital stay and prevents recurrent biliary events without increasing surgical morbidity. Furthermore, the management of high-risk surgical candidates—those previously managed exclusively with percutaneous cholecystostomy (PC)—is currently being refined through rigorous multicenter trials.

Early vs. Delayed Laparoscopic Cholecystectomy (Yadav et al.)

Historically, surgeons preferred to delay LC for 6 to 8 weeks following an acute episode of cholecystitis, believing that allowing inflammation to subside would reduce the risk of bile duct injury and conversion to open surgery. However, this 'delayed' approach often resulted in interval biliary symptoms, emergency readmissions, and technically difficult surgeries due to chronic scarring.

In a prospective randomized clinical trial, Yadav et al. ^[99] compared the outcomes of early versus delayed LC in 50 patients with acute calculus cholecystitis. The study population had a mean age of approximately 40-42 years and a female-to-male ratio of 3.16:1 ^[99]. The trial focused on the frequency of intraoperative and postoperative complications, as well as the rate of conversion to open surgery.

Key Findings and Clinical Reasoning:

• Feasibility: The study demonstrated that early LC is a safe and feasible intervention for acute cholecystitis ^[99].
• Surgical Plane: The rationale for early intervention (ideally within 72 hours of symptom onset) is that the early inflammatory phase is characterized by edema, which can facilitate the dissection of the Calot triangle . In contrast, delayed surgery often encounters dense, organized adhesions that obscure anatomy.
• Resource Utilization: By performing the surgery during the index admission, the total duration of hospital stay is significantly reduced, and the risk of 'interval' cholecystitis—which can occur while the patient is waiting for their scheduled delayed surgery—is eliminated ^[99].

The CHOCOLATE Trial: PC vs. LC in High-Risk Patients

While early LC is the gold standard for most patients, the management of 'high-risk' surgical candidates remains controversial. High-risk patients are often defined by significant physiological derangement, such as those with an APACHE-II score between 7 and 14 ^[100]D. For these individuals, percutaneous cholecystostomy (PC) has traditionally been used as a less invasive alternative to surgery, either as a bridge to later LC or as definitive therapy.

The CHOCOLATE trial (Kortram et al., 2012) was designed as a randomized, multicenter, superiority trial to provide evidence-based guidance for this specific population ^[100]D. The trial enrolled patients from 30 high-volume teaching hospitals, randomizing them to either LC or PC ^[100]D.

Trial Design and Objectives:

• Population: Patients with acute calculous cholecystitis and an APACHE-II score of 7-14 ^[100]D.
• Primary Endpoint: A composite endpoint of major complications occurring within 3 months following randomization ^[100]D.
• Clinical Impact: Before this trial, the surgical community lacked high-level evidence to decide between the definitive but physiologically demanding LC and the less invasive but potentially less effective PC. The CHOCOLATE trial was designed to determine if PC truly offers a safety advantage or if the definitive nature of LC leads to better long-term outcomes by preventing recurrent biliary sepsis ^[100]D.

Clinical Impact and Evolution of Practice

The evidence from these landmark studies has solidified the 'early' surgical approach as the standard of care. The shift is supported by the understanding that delaying surgery does not decrease the rate of conversion to open surgery but does increase the overall cost of care and the risk of recurrent gallstone-related complications ^[99]. For the critically ill, the ongoing analysis of trials like CHOCOLATE continues to refine the threshold at which the risks of general anesthesia and surgery outweigh the benefits of definitive gallbladder removal ^[100]D.

Management of acute cholecystitis (AC) requires significant modification in special populations due to atypical presentations, altered physiological reserves, and unique drug-induced toxicities. Clinicians must balance the risks of emergent surgery against the potential for rapid progression to gangrene or perforation, particularly in the elderly and those with significant cardiovascular comorbidities ^[37], ^[79]D.

The Elderly and Frail

Elderly patients are at a disproportionately high risk for gangrenous cholecystitis (GC), a severe complication defined by focal or diffuse necrosis of the gallbladder wall ^[37]. This risk is exacerbated by age-related vascular changes and a higher prevalence of metabolic stress. The triglyceride-glucose (TyG) index, calculated as ln (fasting triglyceride [mg/dL] × fasting glucose [mg/dL] / 2), has emerged as a valuable biomarker for risk stratification in this population; higher TyG values are associated with increased disease severity according to Tokyo Guidelines 2018 ^[74].

For elderly patients who are high-risk surgical candidates (e.g., those with heart failure), percutaneous transhepatic gallbladder drainage (PTGBD) is often employed as a bridge to surgery or as definitive management ^[70]. However, PTGBD is associated with longer hospital stays (18.2 vs. 11.3 days) and higher ICU admission rates (44.3% vs. 22.1%) compared to direct laparoscopic cholecystectomy (LC) ^[70]. When used as a bridge, the optimal timing for interval LC remains debated, though delaying surgery beyond the initial acute phase may increase the risk of major perioperative complications (Clavien-Dindo grade ≥ III) ^[91].

Protocol for Surgically Unfit Elderly Patients

1. Initial Stabilization: Aggressive fluid resuscitation and broad-spectrum antibiotics .
2. Drainage: Perform PTGBD or endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) if LC is contraindicated ^[75]D. EUS-GBD using a 19-gauge needle and modified slim metal stents is a feasible alternative in patients with malignant biliary obstruction ^[75]D.
3. Tube Management: If PTGBD is performed, early vs. delayed tube removal does not significantly alter recurrence rates, provided the patient has achieved clinical resolution ^[68].
4. Definitive Treatment: Re-evaluate for interval LC once comorbidities are optimized ^[91].

Pregnancy and the Parturient

While laparoscopic cholecystectomy is the standard of care for AC, pregnancy necessitates careful timing to minimize fetal risk. Surgery is generally preferred in the second trimester to avoid the teratogenic risks of the first trimester and the technical difficulties/ preterm labor risks of the third trimester ^[92]. In cases of perforated cholecystitis, early cholecystectomy (same-admission) is preferred over interval surgery, as interval management is associated with a higher rate of conversion to open surgery (55.2% vs. 35.3%) and increased surgical site infections ^[69].

Immunocompromised and Oncology Patients

Oncology patients receiving specific targeted therapies are at risk for acalculous cholecystitis. Notably, Lenvatinib (an oral multi-kinase inhibitor used for renal cell and hepatocellular carcinoma) has been linked to drug-induced acalculous cholecystitis ^[101]C. Presentation may be insidious, with radiological findings such as gallbladder wall thickening and pericholecystic fluid occurring even in the absence of classic abdominal pain ^[101]C.

In patients with malignant biliary obstruction (MBO) undergoing ERCP, the use of peri-procedural antibiotics is critical to prevent post-procedural cholecystitis, particularly when a stent is placed across the cystic duct orifice ^[78]D. For those who are surgically unfit due to advanced malignancy, EUS-GBD via transgastric or transduodenal routes provides effective symptom relief with high clinical success rates ^[76]D.

Obese Patients

Obese patients are at higher risk for port-site complications, including umbilical port-site hernias (PSH). Evidence suggests that using a 5 mm umbilical port and telescope (mini-laparoscopic cholecystectomy) instead of the standard 10 mm port significantly reduces postoperative pain and the incidence of PSH without increasing operative time or compromising surgeon satisfaction ^[65].

Patients with Cardiovascular Comorbidities

Pre-existing heart failure (HF) is a significant independent predictor of poor outcomes following LC for acute cholecystitis. Patients with HF experience higher in-hospital mortality, longer hospital stays, and increased total hospital costs ^[79]D. In these patients, the decision between early surgery and gallbladder drainage must be individualized, prioritizing hemodynamic stability and minimizing the duration of general anesthesia.

The management of acute cholecystitis (AC) has evolved significantly with the integration of advanced imaging protocols, minimally invasive drainage techniques, and refined surgical timing. Current clinical practice is primarily guided by the Tokyo Guidelines 2018 (TG18) framework, supplemented by recent updates from the Infectious Diseases Society of America (IDSA), the American College of Radiology (ACR), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).

Diagnostic Imaging Guidelines

Recent updates from the IDSA ^[107] and the ACR ^[109] reinforce the diagnostic hierarchy for suspected biliary disease. Ultrasound remains the initial imaging modality of choice due to its high sensitivity for gallstones and gallbladder wall thickening without the risks of ionizing radiation.

• First-line: Ultrasound of the right upper quadrant (RUQ) is recommended for all patients presenting with RUQ pain ^[107][109].
• Second-line/Equivocal cases: Cholescintigraphy (HIDA scan) is recommended when ultrasound is inconclusive but clinical suspicion remains high ^[107].
• Extrabiliary Evaluation: CT imaging is utilized primarily when complications (e.g., perforation, gangrene) are suspected or to rule out extrabiliary causes of RUQ pain, such as pancreatitis or liver abscess ^[109].

Management of High-Risk and Unfit Patients

For patients who are critically ill or have significant comorbidities (e.g., ASA score >3), the Italian Society of Emergency Surgery and Trauma (SICUT) and the American Gastroenterological Association (AGA) provide specific pathways to avoid the high morbidity of emergency surgery ^[108][110].

Protocol: Management of the Surgical High-Risk Patient

1. Step 1: Risk Stratification: Utilize the TG18 severity grading and ASA physical status to determine if the patient can tolerate general anesthesia ^[108][112].
2. Step 2: Initial Stabilization: Initiate IV fluids and appropriate antibiotic therapy based on local resistance patterns ^[107].
3. Step 3: Drainage Selection: If the patient is unfit for surgery, select a drainage method. While percutaneous cholecystostomy (PC) has been the traditional standard, EUS-guided gallbladder drainage (EUS-GBD) using lumen-apposing metal stents (LAMS) is now recommended as a feasible and efficacious alternative in centers with advanced endoscopic expertise ^[110].
4. Step 4: Re-evaluation: Assess for clinical improvement within 48–72 hours. If the patient stabilizes, elective cholecystectomy may be considered at a later date, though the optimal timing after drainage remains a subject of ongoing research ^[114].

Surgical Innovation and Safety

Laparoscopic cholecystectomy remains the gold standard for AC ^[113]. To improve safety, particularly in difficult cases (TG18 Grade II or III), the use of near-infrared fluorescent cholangiography (NIRF-C) is emerging as a tool to better visualize the biliary anatomy and reduce the risk of bile duct injury ^[111].

In the context of the COVID-19 pandemic, SAGES (2025) issued updated guidelines regarding patients with concomitant infection. For COVID-positive patients, the panel suggests that either operative or nonoperative management is acceptable, depending on the severity of the infection and the surgical urgency ^[105].

Severity Prediction and Biomarkers

While TG18 provides a robust framework for grading severity, it requires multiple parameters. Recent evidence suggests that Monocyte Distribution Width (MDW) may serve as a useful biomarker for early detection of sepsis and prediction of severe cholecystitis (defined by ICU admission or mortality), potentially simplifying the initial triage process ^[112].

Comparative Guideline Summary

Clinical Prediction Tools

• TG18/TG13 Severity Grading: The primary tool for classifying AC into Grade I (mild), Grade II (moderate), and Grade III (severe) based on local inflammation and organ dysfunction ^[112].
• ASA Physical Status Classification: Used to determine fitness for general anesthesia and the necessity of alternative drainage procedures ^[108][111].

Patient Information Resources

• SAGES Patient Information: Guidance on what to expect during a laparoscopic cholecystectomy.
• ACR Patient Resources: Information regarding the safety and necessity of RUQ ultrasound and HIDA scans.